Try our beta test site
15 studies found for:    crizotinib | Open Studies | lymphoma
Show Display Options
Rank Status Study
1 Recruiting Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
Condition: Anaplastic Large Cell Lymphoma, ALK-Positive
Intervention: Drug: crizotinib
2 Recruiting A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Interventions: Drug: Alectinib;   Drug: Crizotinib
3 Recruiting Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions: Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: questionnaire administration
4 Recruiting Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   CD30-Positive Neoplastic Cells Present;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate
5 Recruiting Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Alectinib;   Drug: Docetaxel;   Drug: Pemetrexed
6 Recruiting A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Non-Small Cell Lung Cancer (ALK-positive);   Non-Small Cell Lung Cancer (c-Met Dependent);   Non-Small Cell Lung Cancer (ROS Marker Positive);   Systemic Anaplastic Large-Cell Lymphoma;   Advanced Malignancies (Except Leukemia)
Interventions: Drug: PF-02341066;   Drug: Rifampin;   Drug: Itraconazole
7 Recruiting eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Condition: Non-small Cell Lung Cancer
Interventions: Drug: X-396 (ensartinib);   Drug: crizotinib
8 Recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
9 Recruiting CREATE: Cross-tumoral Phase 2 With Crizotinib
Conditions: Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma;   Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor;   Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1;   Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma;   Locally Advanced and/or Metastatic Clear Cell Sarcoma;   Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma
Intervention: Drug: Crizotinib (PF-02341066)
10 Not yet recruiting A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Lorlatinib;   Drug: Crizotinib
11 Recruiting TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Advanced Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Axitinib;   Drug: Bosutinib;   Drug: Crizotinib;   Drug: Palbociclib;   Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Trastuzumab and Pertuzumab;   Drug: Vemurafenib and Cobimetinib;   Drug: Vismodegib;   Drug: Cetuximab;   Drug: Dasatinib;   Drug: Regorafenib;   Drug: Olaparib;   Drug: Pembrolizumab
12 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Trk Inhibitor LOXO-101;   Drug: Vismodegib;   Drug: WEE1 Inhibitor AZD1775
13 Recruiting ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Interventions: Drug: Brigatinib;   Drug: Xalkori (crizotinib)
14 Recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Conditions: Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
Intervention: Drug: Entrectinib
15 Recruiting High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
Conditions: Acute Leukemia of Ambiguous Lineage;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Chemosensitivity Assay;   Other: Cytology Specimen Collection Procedure;   Genetic: Gene Expression Analysis;   Drug: In Vitro Sensitivity-Directed Chemotherapy;   Genetic: Mutation Analysis

Study has passed its completion date and status has not been verified in more than two years.